Probiotics

Probiotics are live microorganisms studied across an unusually broad range of indications: antibiotic-associated diarrhea (the most-clinically-established use), irritable bowel syndrome (IBS), pediatric acute infectious diarrhea, Clostridioides difficile infection prevention, inflammatory bowel disease, allergic conditions, immune support, mood and the gut-brain axis (a rapidly growing research area), and women's health applications including bacterial vaginosis. The most-studied genera are Lactobacillus, Bifidobacterium, and Saccharomyces boulardii (a yeast); individual species and strains within these genera have substantially different effects, which is the most-important practical detail in the entire literature.

The outcome dimensions covered most heavily are antibiotic-associated diarrhea in adults and children (the most-clinically-established use, with practice-guideline endorsement from major pediatric and adult gastroenterology bodies), irritable bowel syndrome (multiple network meta-analyses), inflammatory bowel disease (mixed evidence depending on indication and strain), prevention of nosocomial infections in specific populations, atopic dermatitis prevention in infants of allergic parents, and (more recently) mood and anxiety in the broader gut-brain-axis literature. The World Gastroenterology Organisation maintains a global practice guideline that organizes the field around strain-and-indication-specific recommendations.

Demographically, the literature is unusually broad across populations: pediatric diarrhea trials dominate the public-health side of probiotic research; older adults are heavily studied for AAD prevention; women of reproductive age feature in vaginal-health research. Strain specificity is the central methodological and consumer-relevant issue: meta-analyses sometimes pool trials by intervention category (for example, 'probiotics for IBS') rather than by specific strain, which dilutes the signal. Consumer products often disclose only the genus and species but not the specific strain identifier, which makes evidence-matching difficult in practice.

Probiotics are generally well-tolerated in healthy individuals at recommended doses. The most-common adverse effects are transient bloating, gas, and abdominal discomfort, typically self-limited. No tolerable upper limit has been established. The major safety concerns are not in healthy users but in specific clinical populations: immunocompromised individuals (chemotherapy, transplant recipients, advanced HIV), critically ill patients (especially with central venous catheters, where rare cases of bacteremia or fungemia have been reported), preterm infants (the subject of a 2023 FDA warning), and individuals with severely compromised gut barrier function. Drug interactions are minimal. People in any of the high-risk clinical populations should consult a clinician before use.

This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.